Michael A. Newton

About

Michael A. Newton is a Professor in the Departments of Statistics and of Biostatistics and Medical Informatics (BMI) at the University of Wisconsin-Madison. He has been serving as chair of BMI since October 2019. Dr. Newton directs the Biostatistics and Epidemiology Research and Design (BERD) core of the Institute for Clinical and Translational Research and is a member of the Carbone Comprehensive Cancer Center, the Center for Genome Science and Innovation, and other campus research units. He currently co-chairs the Council of North American Biostatistics Chairs. Dr. Newton's research focuses on data science for basic and translational biomedicine, with contributions spanning cancer biology, immunology, genomics, methodologies for high-dimensional biostatistical inference, and theory for computational statistics. His work has been especially focused on empirical Bayesian inference calculations and has been strengthened by interdisciplinary collaborations and mentorship of talented PhD students. Dr. Newton's work has been recognized by several professional societies. He received the 2003 Mortimer Spiegelman Award from the American Public Health Association, honoring an outstanding public health statistician under age 40, and in 2004, he was named the Presidents' Award winner from the Committee of Presidents of Statistical Societies (COPSS), one of the profession's most prestigious awards. He is an elected fellow of the American Statistical Association and an elected member of…

Research topics

• Artificial Intelligence
• Data Mining
• Computer Science
• Biology
• Genetics
• Cancer research
• Internal medicine
• Immunology
• Simulation
• Oncology

Selected publications

• SpotClean adjusts for spot swapping in spatial transcriptomics data

  Nature Communications · 2022 · 79 citations

  Spatial transcriptomics is a powerful and widely used approach for profiling the gene expression landscape across a tissue with emerging applications in molecular medicine and tumor diagnostics. Recent spatial transcriptomics experiments utilize slides containing thousands of spots with spot-specific barcodes that bind RNA. Ideally, unique molecular identifiers (UMIs) at a spot measure spot-specific expression, but this is often not the case in practice due to bleed from nearby spots, an artifac…

  DOI

• Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade

  Science Translational Medicine · 2024-09-18 · 56 citations

  articleOpen access

  Radiation therapy (RT) activates multiple immunologic effects in the tumor microenvironment (TME), with diverse dose-response relationships observed. We hypothesized that, in contrast with homogeneous RT, a heterogeneous RT dose would simultaneously optimize activation of multiple immunogenic effects in a single TME, resulting in a more effective antitumor immune response. Using high-dose-rate brachytherapy, we treated mice bearing syngeneic tumors with a single fraction of heterogeneous RT at a…

  PublisherOA PDFDOI

• Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages

  Journal for ImmunoTherapy of Cancer · 2020 · 21 citations

  BACKGROUND: Previous studies of prostate cancer autoantibodies have largely focused on diagnostic applications. So far, there have been no reports attempting to more comprehensively profile the landscape of prostate cancer-associated antibodies. Specifically, it is unknown whether the quantity of antibodies or the types of proteins recognized change with disease progression. METHODS: A peptide microarray spanning the amino acid sequences of the gene products of 1611 prostate cancer-associated ge…

  DOI

• Ancestral Folate Promotes Neuronal Regeneration in Serial Generations of Progeny

  Molecular Neurobiology · 2020 · 19 citations

  PublisherOA PDFDOI

• NK cells propagate T cell immunity following in situ tumor vaccination

  Cell Reports · 2023-12-01 · 15 citations

  articleOpen access

  We report an in situ vaccination, adaptable to nearly any type of cancer, that combines radiotherapy targeting one tumor and intratumoral injection of this site with tumor-specific antibody and interleukin-2 (IL-2; 3xTx). In a phase I clinical trial, administration of 3xTx (with an immunocytokine fusion of tumor-specific antibody and IL-2, hu14.18-IL2) to subjects with metastatic melanoma increases peripheral CD8+ T cell effector polyfunctionality. This suggests the potential for 3xTx to promote…

  PublisherOA PDFDOI

Recent grants

• NIH Grant T32GM074904

  NIH · $1.5M · 2014

• NIH Grant R21HG006568

  NIH · $356k · 2015

• Cancer Center Administration

  NIH · $99.8M · 1997–2028

Frequent coauthors

• Linda Clipson

  90 shared

• Kristina A. Matkowskyj

  Mayo Clinic in Arizona

  68 shared

• Dustin A. Deming

  University of Wisconsin Carbone Cancer Center

  66 shared

• Richard B. Halberg

  University of Wisconsin–Madison

  65 shared

• Paul Ahlquist

  Morgridge Institute for Research

  61 shared

• Mark R. Albertini

  University of Wisconsin Carbone Cancer Center

  60 shared

• Irene M. Ong

  University of Wisconsin–Madison

  49 shared

• Cheri A. Pasch

  University of Wisconsin–Madison

  41 shared

Education

• Ph.D., Biostatistics

  University of Wisconsin-Madison

  1994

• M.S., Statistics

  University of Wisconsin-Madison

  1989

• B.S., Mathematics

  University of Wisconsin-Madison

  1986

Similar researchers at University of Wisconsin-Madison

• Ron Gangnonh-85
• Karl Bromanh-68
• Sushmita Royh-56